Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BRS3 | P32247 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422174 | 1.00 | AKT1 (0.53) | AKT1NAMPTCA1CA2HCAR2 | |
| SCHEMBL26847061 | 0.89 | AKT1 (0.52) | AKT1NAMPTACACBACACATRPV1 | |
| SCHEMBL30608878 | 0.89 | AKT1 (0.52) | AKT1NAMPTACACBACACATRPV1 | |
| SCHEMBL23291127 | 0.86 | AKT1 (0.53) | AKT1NAMPTCA1CA2NR1H2 | |
| SCHEMBL18800977 | 0.83 | NAMPT (0.58) | AKT1NAMPTCA1CA2NR1H2 | |
| SCHEMBL17273999 | 0.83 | CKS1B (0.50) | AKT1NAMPTCA1CA2ACACB | |
| SCHEMBL23291128 | 0.81 | CYP17A1 (0.59) | AKT1NAMPTCA1CA2PTGER4 | |
| SCHEMBL6692 | 0.81 | TRPV1 (0.44) | AKT1NAMPTCA1HCAR2ACACB | |
| SCHEMBL30637051 | 0.81 | TRPV1 (0.44) | AKT1NAMPTCA1HCAR2ACACB | |
| SCHEMBL23828889 | 0.80 | HCAR2 (0.55) | HCAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814355-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| CN-111164084-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | AKT1 1265/4885NAMPT 1862/4885CA1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.